Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives $77.13 Consensus Price Target from Brokerages

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) has been given an average rating of “Buy” by the seventeen ratings firms that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, fourteen have issued a buy recommendation and two have given a strong buy recommendation to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $77.1333.

A number of equities research analysts recently weighed in on XENE shares. Wells Fargo & Company reaffirmed an “overweight” rating and set a $69.00 price objective on shares of Xenon Pharmaceuticals in a research report on Sunday, May 10th. Weiss Ratings restated a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a research note on Monday, July 6th. HC Wainwright restated a “buy” rating and issued a $74.00 target price on shares of Xenon Pharmaceuticals in a research note on Monday, August 10th. JPMorgan Chase & Co. upped their target price on Xenon Pharmaceuticals from $80.00 to $82.00 and gave the company an “overweight” rating in a report on Wednesday, May 27th. Finally, Needham & Company LLC dropped their price target on Xenon Pharmaceuticals from $80.00 to $78.00 and set a “buy” rating on the stock in a research report on Friday, May 8th.

Xenon Pharmaceuticals Stock Performance

XENE stock opened at $62.35 on Friday. The stock’s 50 day simple moving average is $61.34 and its 200 day simple moving average is $55.08. Xenon Pharmaceuticals has a 12-month low of $35.60 and a 12-month high of $72.66. The firm has a market cap of $6.03 billion, a P/E ratio of -13.15 and a beta of 0.62.

Xenon Pharmaceuticals (NASDAQ:XENE) last released its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($1.11) EPS for the quarter, topping analysts’ consensus estimates of ($1.16) by $0.05. During the same quarter last year, the company posted ($1.07) earnings per share. On average, research analysts forecast that Xenon Pharmaceuticals will post -4.73 EPS for the current fiscal year.

Insider Activity at Xenon Pharmaceuticals

In other Xenon Pharmaceuticals news, Director Gary Patou sold 1,322 shares of the stock in a transaction on Friday, June 5th. The stock was sold at an average price of $53.14, for a total value of $70,251.08. Following the sale, the director directly owned 24,896 shares of the company’s stock, valued at $1,322,973.44. This trade represents a 5.04% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Steven Gannon sold 10,000 shares of the firm’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $64.06, for a total value of $640,600.00. Following the completion of the sale, the director owned 1,870 shares in the company, valued at $119,792.20. The trade was a 84.25% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 12,512 shares of company stock worth $774,088 in the last 90 days. 2.91% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Xenon Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of the company. Kestra Advisory Services LLC acquired a new position in shares of Xenon Pharmaceuticals during the fourth quarter valued at $33,000. Danske Bank A S acquired a new stake in Xenon Pharmaceuticals in the third quarter worth about $32,000. Global Retirement Partners LLC acquired a new stake in Xenon Pharmaceuticals in the second quarter worth about $53,000. Quantbot Technologies LP bought a new position in Xenon Pharmaceuticals in the 2nd quarter valued at about $57,000. Finally, Caitong International Asset Management Co. Ltd bought a new position in Xenon Pharmaceuticals in the 4th quarter valued at about $43,000. Institutional investors and hedge funds own 95.45% of the company’s stock.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.